biotech.today

Details

  • ●Modalities: genomics platform, radiomics, multimodal analytics
  • ●Therapeutic areas: oncology, rare diseases, hereditary conditions
  • ●Key targets:
  • ●Indications: solid tumors (genomic profiling), hereditary cancer, rare genetic diseases
  • ●Funding: $249M+ (pre-IPO)

Partners & investors

  • Public (Nasdaq: SOPH)· Investor
  • Balderton Capital· Investor
  • Generation Investment Management· Investor
  • Endeavour Vision· Investor

Key considerations

  • ●AI tools in use: SOPHiA DDM (Data-Driven Medicine platform), SOPHiA Radiomics, SOPHiA Clinical Trials
  • ●780+ hospital customers globally
  • ●1M+ genomic profiles analyzed
  • ●AI-powered variant interpretation
Get live updates on SOPHiA GENETICS’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Jurgi Camblong

Co-Founder & CEO

genomicsbioinformaticshealth data analytics
Visit website →LinkedIn →